Join us for an exclusive gathering of senior-level investors, pharma executives, entrepreneurs, research thought leaders, and innovators at the 33rd Annual TRI-CON. Connect with investors and partners at intimate networking...
Join our SynBioBeta community for three days of high-signal talks, curated 1:1 meetings, real partnering, and hands-on exposure at the frontier of biology and technology. Go deep on AI-driven biology...
A practical look at overcoming viscosity, fouling, and aggregation with modern TFF platforms. As monoclonal antibody therapies continue to evolve, the industry is rapidly shifting from traditional mAb formulations to...
Selective gene delivery to defined cell populations using targeted lentiviral vectors (LVV) represents a promising strategy for next‑generation immunotherapies such as chimeric antigen receptor (CAR) T‑cell therapy. While conventional CAR-T...
